Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial

DSpace Repository

Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial

Author: Pfisterer, Jacobus; Joly, Florence; Kristensen, Gunnar; Rau, Joern; Mahner, Sven; Pautier, Patricia; El-Balat, Ahmed; Kurtz, Jean-Emmanuel; Canzler, Ulrich; Sehouli, Jalid; Heubner, Martin L.; Hartkopf, Andreas D.; Baumann, Klaus; Hasenburg, Annette; Hanker, Lars C.; Belau, Antje; Schmalfeldt, Barbara; Denschlag, Dominik; Park-Simon, Tjoung-Won; Selle, Frederic; Jackisch, Christian; Burges, Alexander; Lueck, Hans-Joachim; Emons, Guenter; Meier, Werner; Gropp-Meier, Martina; Schroeder, Willibald; de Gregorio, Nikolaus; Hilpert, Felix; Harter, Philipp
Tübinger Autor(en):
Hartkopf, Andreas
Published in: Journal of Clinical Oncology (2023), Bd. 41, H. 4, S. 893-902
Verlagsangabe: Lippincott Williams & Wilkins
Language: English
Full text: http://dx.doi.org/10.1200/JCO.22.01010
ISSN: 0732-183X
DDC Classifikation: 610 - Medicine and health
Dokumentart: Article
Show full item record

This item appears in the following Collection(s)